Qualifying Therapeutic Discovery Project Grants for the State of Massachusetts
The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.
The project descriptions below were extracted from the applicant certification forms as submitted.
| Applicant Name | Project Name | Grants Awarded for 2009 | Grants Awarded for 2010 |
|---|---|---|---|
| 3G Biotech, LLC | Use of Zinc Chelators to inhibit Biofilm Formation | $ 244,479.24 | |
| 3W Consulting Co | Multiparameter Screening Method and Multicomponent Drug for Cardiovascular Disease | $ 240,250.00 | $ 4,229.24 |
| 4s3 Bioscience, Inc | Intravenous Protein Therapy by Myotonic Dystrophy Type 1 | $ 189,538.00 | $ 54,941.24 |
| Acceleron Pharma, Inc | ACE-031 | $ 244,479.24 | |
| Acceleron Pharma, Inc. | ACE-536 | $ 244,479.25 | |
| Acceleron Pharma, Inc. | ACE-435 | $ 244,479.24 | |
| Acceleron Pharma, Inc. | ACE-011 Anemia | $ 244,479.24 | |
| Acceleron Pharma, Inc. | ACE-041 | $ 244,479.24 | |
| Acetylon Pharmaceuticals Inc | Development of novel cancer drug candidate ACY-1215 | $ 244,479.25 | |
| ACETYLON PHARMACEUTICALS, INC. | ACY-257 A NOVEL HDAC6 INHIBITOR DRUG CANDIDATE FOR INFLAMMATORY DISEASES | $ 152,965.50 | $ 91,513.75 |
| Aciex Therapeutics, Inc | AC-100 Treatmenty for Signs and Symptoms of Dry Eye Syndrome | $ 244,479.24 | |
| Aciex Therapeutics, Inc. | AC-120 TREATMENT FOR CHRONIC EYELID EDEMA | $ 244,479.24 | |
| Aciex Therapeutics, Inc. | AC-200- Treatment for Meibomian Gland Disease | $ 244,479.24 | |
| ACIEX THERAPEUTICS, INC. | AC-150- TREATMENT FOR COMPREHENSIVE ALLERGIC CONJUNCTIVITIS | $ 244,479.24 | |
| Acton Pharmaceuticals, Inc. | Aerospan (flunisolide hfa 80 mcg) Inhalation Aerosol | $ 244,479.25 | |
| Acusphere, Inc | AI-700- (perflubutane polymer microspheres) for Injectable Suspension | $ 244,479.25 | |
| AdvanDx Inc. | PNA FISH | $ 244,479.24 | |
| Advantagene Inc | Development of PancAtak for Panceatic Cancer | $ 20,290.00 | $ 124,128.00 |
| Advantagene, Inc. | Development of GliAtak for malignant brain tumors | $ 244,479.25 | |
| Advantagene, Inc. | Development of ProstAtak™ for Prostate Cancer | $ 101,602.00 | $ 142,877.25 |
| AesRX, LLC | AES-103: A new targeted treatment of Sickle Cell Disease | $ 173,806.92 | $ 70,672.33 |
| Agios Pharmaceuticals | Developing novel cancer therapies targeting the key metabolic enzyme PKM2 | $ 244,479.25 | |
| Agios Pharmaceuticals | Developing novel targeted therapies for gliomas & AML harboring IDH2 & IDH2 mutations | $ 244,479.25 | |
| Aileron Therapeutics, Inc | BIM Mimetic for Oncology | $ 244,479.24 | |
| Aileron Therapeutics, Inc. | Stapled Peptide Therapeutic Pipeline | $ 244,479.24 | |
| Alfama, Inc. | Development of a novel drug to treat acetaminophen-induced acute liver failure (ALF) | $ 244,479.24 | |
| Alfama, Inc. | Synthesis of improved CORMs to treat acute liver failure and post-operative ileus | $ 244,479.24 | |
| Alfama, Inc. | Development of a novel drug to prevent to treat post-operative ileus (POI). | $ 63,658.34 | $ 47,794.70 |
| Alkeus Pharmaceuticals Inc | Assessment of ALK001 for the prevention of vision loss in dry macular degeneration | $ 129,437.00 | $ 115,042.25 |
| Allegro Diagnostics | Product Development for BronchoGen (AEGIS Trial) | $ 244,479.25 | |
| Alnylam Pharmaceuticals Inc | Single Strand RNAi Technology Platform | $ 244,479.24 | |
| Alnylam Pharmaceuticals Inc | Alnylam Biotherapeutics | $ 244,479.24 | |
| Alnylam Pharmaceuticals Inc. | ALN-VSP for Liver Cancer | $ 244,479.24 | |
| Alnylam Pharmaceuticals, Inc | RNAi Therapeutic Delivery Platform | $ 244,479.24 | |
| Alnylam Pharmaceuticals, Inc | ALN-HTT for Huntington's Disease | $ 244,479.24 | |
| Alnylam Pharmaceuticals, Inc | ALN-PCS for the treatment of Hypercholesterolemia | $ 244,479.24 | |
| Alnylam Pharmaceuticals, Inc. | ALN-RSV for Respiratory Syncytial Virus (RSV) infection | $ 244,479.24 | |
| Alnylam Pharmaceuticals, Inc. | ALN-TTR for the Treatment of Transthyrein-mediated Amyloidosis (ATTR) | $ 244,479.24 | |
| Alzcor Pharmaceuticals Inc | Modulators of Amyloid Precursor protein(APP)Processing | $ 2,000.00 | |
| AmberGen, Inc. | Development of Diagnostic and Prognostic Cancer Assays For Personalized Medicine | $ 244,479.25 | |
| AmelioMed, LLC | Minimally Invasive Targeted Therapeutic Hypothermia for the Treatment of Spinal Cord Injury | $ 4,755.93 | |
| Anchor Therapeutics, Inc. | Novel long-lived peptide allosteric G protein coupled receptor modulators | $ 244,479.25 | |
| Ancora Pharmaceuticals Inc | Synthetic Carbohydrate-Based Staphylococcal Vaccine Program | $ 244,479.25 | |
| Ancora Pharmaceuticals, Inc | Synthetic Carbohydrate-Based Malaria Vaccine Program | $ 220,853.50 | $ 23,625.75 |
| Anexon Inc | ANX-042 treatment of acute decompensated haert failure (ADHF) | $ 244,479.25 | |
| Antigen Express Inc | Ii-Key Her-2/neu Peptide Vaccine, AE37, for the treatment of breast cancer. | $ 244,479.25 | |
| Antigen Express, Inc | li-Key Her-2/neu Peptide Vaccine, AE37, for the treatment of prostate cancer | $ 244,479.25 | |
| Antigenics Inc. | AG-707, Inveestigational therapeutic vaccine for treatment of genital herpes | $ 59,891.00 | $ 120,350.00 |
| Antigenics Inc.(a Massachusetts corporation) | QS-21, Vaccine adjuvant under development to treat infections, cancers, and Alzheimers | $ 244,479.25 | |
| Antisoma Inc | Amonafide: evading drug resistance in leukemia | $ 244,479.24 | |
| Aphios Corporation | Development of Zindol, a Novel Anti-Nausea Drug | $ 80,968.50 | $ 106,759.00 |
| Aphios Corporation | Phospholipid Nanosomes Drug Delivery | $ 82,652.50 | $ 51,873.50 |
| Aphios Corporation | Pathogen Inactivation of Human Plasma | $ 83,801.00 | $ 160,678.25 |
| AQUILUS PHARMACEUTICALS INC | Development of AQU-010 for Neuropathic Pain | $ 5,460.00 | $ 11,714.50 |
| Archemix Corp | Hemophilia-ARC19499 | $ 244,479.25 | |
| ARIAD PHARMACEUTICALS, INC | mTOR Inhibitor-Ridaforolimus | $ 244,479.24 | |
| ARIAD PHARMACEUTICALS, INC | ALK Inhibitor-AP26113 | $ 244,479.24 | |
| ARIAD PHARMACEUTICALS, INC | Pan BCR-ABL Inhibitor- AP24534 | $ 244,479.24 | |
| ARIETIS CORPORATION | Antifungal therapies for the treatment of recalcitrant and recurrent Candida albicans infection | $ 76,354.91 | $ 168,124.34 |
| Arisaph Pharmaceuticals Inc | Niacin Mimetics | $ 244,479.25 | |
| Arisaph Pharmaceuticals Inc | APO A1 Mimetics | $ 102,759.50 | $ 132,924.00 |
| Arisaph Pharmaceuticals Inc | GLP-1 | $ 120,236.00 | $ 117,636.00 |
| Arisaph Pharmaceuticals Inc. | Endothelial Lipase Inhibitors | $ 148,986.00 | $ 95,493.25 |
| Arisaph Pharmaceuticals, Inc | Small Molecule Enhancers for Cancer Vaccines | $ 179,287.50 | $ 65,191.75 |
| Arisaph Pharmaceuticals, Inc | Stabilized Peptide Hormones | $ 111,473.50 | $ 67,985.50 |
| Arisaph Pharmaceuticals, Inc | Tumor-Activated Prodrugs | $ 244,479.25 | |
| ARISAPH PHARMACEUTICALS, INC | OBESITY/METABOLIC DISORDERS-MULTIMEDIATORS | $ 198,579.00 | $ 45,900.25 |
| Arisaph Pharmaceuticals, Inc | Tumor Diagnotics | $ 150,059.50 | $ 94,419.75 |
| Arisaph Pharmaceuticals, Inc. | DPP-4 Inhibitors | $ 244,479.25 | |
| Arisaph Pharmaceuticals, Inc. | Kinetically Dosed Tumor Selective Proteosome Inhibitors | $ 181,868.50 | $ 62,610.75 |
| Arisaph Pharmaceuticals, Inc. | Stable NPY Analogs | $ 111,046.50 | $ 67,610.50 |
| Arqule Inc | Inhibitors of Mutant BRAF Kinase in Cancer | $ 244,479.24 | |
| Arqule Inc | ARQ 621 Cancer Drug Project | $ 244,479.24 | |
| Arqule, Inc. | ARQ-197 Cencer Drug Development Project | $ 244,479.24 | |
| Arqule, Inc. | ARQ -087 Fibroblast Growth Factor Receptor (FGFR) inhibitor Project | $ 244,479.24 | |
| Arsenal Medical, Inc. | Therapeutic Drug Delivery Bioabsorbable Vascular Stent | $ 244,479.25 | |
| Artisan Pharma Inc | ART-123 | $ 244,479.25 | |
| Aspen Medisys LLC | Magnetic Hanoportide Thermathempy for treating cancer | $ 244,479.25 | |
| Attention Therapeutics, Inc. | Development of Attention Therapeutic System for regulatory clearance/commercialization. | $ 173,371.50 | |
| Audax Medical, Inc | Twin-base linker (TBL) bone augmentation | $ 206,885.00 | |
| Augmenix, Inc | SpaceOAR | $ 244,479.25 | |
| Aura Biosciences Inc | Development of a topical self-administered treatment for cervical and anal dysplasia | $ 244,479.24 | |
| Aura Medsystems, Inc. | Light-activated Soft Tissue Repair (laSTR) | $ 206,804.50 | $ 37,674.75 |
| Auxocell laboratories, Inc. | Co - Transplanation of Wharton's Jellly Stem Cells and Cord Blood Stem Cells | $ 244,479.24 | |
| Auxocell Laboratories, Inc. | Medical Device to Process Wharton's Jelly Stem Cells | $ 200,000.00 | $ 44,479.24 |
| Avaxia Biologics, Inc | Development of AVX-470 for the treatment of Gastrointestinal Inflammatory Disorders | $ 24,168.78 | $ 220,310.46 |
| Avedro, Inc. | Novel Therapy Using Microwave and Ultraviolet Energy to Treat Degenerative Corneal Disease | $ 244,479.25 | |
| AVEO Pharmaceuticals, Inc | Tivozanib-A Potent and Selective Triple VEGF-R Inhibitor | $ 244,479.25 | |
| AVEO Pharmaceuticals, Inc | AV-299- A Novel HGF/c-Met Inhibitor | $ 244,479.25 | |
| AVEO Pharmaceuticals, Inc. | Human Response Platform™ and Antibody Programs | $ 244,479.25 | |
| Avila Therapeutics Inc. | Inhibition of Bruton's tyrosine kinase [Btk} to treat blood cancers and autoimmune diseases. | $ 244,479.24 | |
| Avila Therapeutics, Inc | Development of novel therapies, AVL-181 and AVL-192 to treat Hepatitis C Virus infection | $ 244,479.24 | |
| Bach Pharma, Inc | a novel neuroprotective agent | $ 244,479.24 | |
| BG Medicine Inc | The BGM Galectin-3 blood test for predicting development and progression of heart failure | $ 244,479.25 | |
| BG Medicine, Inc. | AMIPredict™ : A novel molecular diagnostic for near-term heart attack or stroke | $ 244,479.25 | |
| Bikam Pharmaceuticals | Pharmacotherapeutics for the Treatment of Retinitis Pigmentosa | $ 244,479.24 | |
| Bind Biosciences, Inc | Development of targeted nanoparticle therapeutics containing highly potent cytonixic agents | $ 244,479.24 | |
| BIND Biosciences, Inc | Development of BIND-014--a solid tumor-targeted nanoparticle containing docetaxel | $ 244,479.24 | |
| BIND Biosciences, Inc | Develop a Medicinal Nanoengineering ™ platform for polymer-based targeted nanoparticle | $ 244,479.24 | |
| BIO2 Technologies, Inc. | Surface Active Tissue Engineering Scaffold | $ 18,614.00 | $ 225,865.24 |
| BIO2 Technologies, Inc. | Resorbable Tissue Engineering Scaffold | $ 55,445.50 | $ 189,033.74 |
| BioAssets Development Corp | Development of a TNF Inhibitor Drug for the Treaments of Sciatica. | $ 244,479.24 | |
| BioBehavioral Diagnostics Company | Expansion of Use of the Quotient ADHD System | $ 230,018.50 | $ 14,460.75 |
| BioChemics Inc | Transdermal Diabetic Neuropathy Treatment (BC-DN-01) | $ 147,004.66 | $ 97,474.59 |
| BioNevia Pharmaceuticals Inc | Arresting progression of diabetic Neuropathy with Epalrestat (BNV-222) | $ 162,689.50 | $ 81,789.74 |
| BioScale, Inc | ViBe platform and AMMP assay for biomarker measurement in therapeutics and Dx | $ 244,479.25 | |
| BioSensics LLC | Sensor-based Auto-BioFeedback and Health Monitoring System | $ 9,250.00 | $ 104,230.00 |
| Bio-Tree Systems, Inc | OncoTree discovery | $ 244,479.25 | |
| Biousian Biosystems Inc | Novel Therapeutics for the treatment of Chronic Pain and Diabetes | $ 61,464.50 | $ 73,113.00 |
| BioVex, Inc. | The OPTiHaN Trial: A Phase 3 Trial to Evaluate OncoVEX in Head and Neck Cancer | $ 2,962.50 | $ 241,516.74 |
| BioVex, Inc. | The OPTiM Trial: A Randomized Phase 3 Clinical Trial to Evaluate OncoVEX | $ 244,479.24 | |
| Birch Tree Medical, Inc. | Use of longterm patient-controlled heat to relieve Restless leg Syndrome | $ 206,000.00 | |
| Boston Biomedical, Inc | BB15600 Anti-Cancer Stem Cell Drug Discovery and Deveopment Program | $ 7,673.39 | $ 236,805.85 |
| Boston Biomedical, Inc. | BBI8000 Anti-Cancer Drug Discovery and Development Program | $ 4,024.94 | $ 240,454.31 |
| Boston Biomedical, Inc. | BB16000 Anti-Cancer Stem Cell Drug Discovery and Development Program | $ 244,479.24 | |
| Boston Endoscopic Engineering Corporation | Therapeutic Gastrointestinal Delivery Platform for EUS fine needle aspiration | $ 185,052.50 | $ 59,426.74 |
| Boston Microfluidics Inc | Rapid Point-of-Care Test Platform | $ 244,479.24 | |
| Braintree Laboratories, Inc | BLI801- SULFATE LAXATIVE | $ 64,956.50 | $ 146,603.50 |
| Braintree Laboratories, Inc. | BLI1100-MEDIDERMIS | $ 152,698.50 | $ 91,780.75 |
| Braintree Laboratories, Inc. | PCD03 - METRONIDAZOLE 10% Ointment | $ 244,479.25 | |
| Cambrooke Foods, LLC | BetterMilk with Glycomacropeptide for Phenylketonuria(PKU) | $ 80,095.50 | |
| Cardiorobotics, Inc. | Articulated Robotic Medprobe (ARM) Robotic System | $ 244,479.25 | |
| Catabasis Pharmaceuticals, Inc | Fatty Acid Salicylate Conjugates as Novel Therapeutics for the Treatment of Type 2 Diabetes | $ 244,479.24 | |
| Celexion LLC | Isolation of Therapeutic Binders to Oncogenic Targets | $ 78,118.00 | $ 166,361.24 |
| Cellay, Inc. | New Method for Cancer Diagnosis | $ 244,479.24 | |
| Cellceutix Corporation | KM-133 for Treatment of Psoriasis | $ 141,984.50 | $ 102,494.75 |
| Cellceutix Corporation | Kevetrin for Cancer Treatment | $ 244,479.25 | |
| Cellceutix Corporation | KM-391 For Treatment of Autism | $ 142,830.00 | $ 101,649.25 |
| Celldex Therapeutics Inc | CDX-301 | $ 244,479.24 | |
| Celldex Therapeutics Inc | CDX-1307 | $ 244,479.24 | |
| Celldex Therapeutics Inc | CDX-011 | $ 244,479.24 | |
| Celldex Therapeutics Inc | CDX-1127 | $ 244,479.24 | |
| Celldex Therapeutics, Inc. | Rindopepimut (CDX-110) | $ 244,479.24 | |
| Celldex Therapeutics, Inc. | CDX-1135 | $ 133,360.50 | $ 111,118.74 |
| Celldex Therapeutics, Inc. | CDX-1401 | $ 244,479.24 | |
| CellThera, Inc. | Functional restoration of a large-scale skeletal muscle defect using dedifferentiated cells | $ 219,093.50 | $ 25,385.74 |
| Celthera, Inc. | Regenerative Platform | $ 25,716.54 | $ 4,803.25 |
| Cephalogics LLC | high-Density Diffuse Optical Tomography for Real-Time Neurological Assessment in Infants | $ 67,612.00 | $ 93,531.70 |
| Cequent Pharmaceuticals, Inc. | CEQ508 | $ 244,479.25 | |
| Cequent Pharmaceuticals, Inc. | CEQ626 | $ 244,479.25 | |
| CeQur Corporation | CeQur Insulin Delivery Device for Use in Type 2 Diabetes | $ 244,479.24 | |
| Cerenova, Inc | Neurostimulation for neurotrauma rehabilitation | $ 244,479.25 | |
| Cerulean Pharma Inc | CRLX101 (formerly IT-101)A Novel Nanopharmaceutical Oncology Agent in Phase 2 | $ 244,479.25 | |
| Cerulean Pharma Inc | Nanopharmaceutical Docetaxel-A Promising Next Generation Oncology Agent | $ 244,479.25 | |
| Cerulean Pharma Inc. | Nanopharmaceutical Drug Delivery Patform Enabling RNA Interference Therapy | $ 244,479.25 | |
| Claros Diagnostics, Inc. | Point-of-Care Diagnostic System for Urologist Office Use | $ 244,479.24 | |
| CombinatoRX ,Inc | Synavive Project | $ 244,479.24 | |
| Combinent Biomedical Systems, Inc. | CBMS-10 | $ 221,188.93 | $ 23,290.31 |
| Concert Medical, LLC | Concert Conductor Guidewire | $ 35, 650.50 | |
| Concert Medical, LLC | Concert N2009 Guidewire | $ 24, 927.00 | |
| Concert Pharmaceuticals, Inc | Novel HIV protease inhibitor not requiring co-dosing with a pharmacokinetic boosting agent | $ 244,479.24 | |
| Concert Pharmaceuticals, Inc | Novel Treatment for Diabetic Nephropathy | $ 244,479.24 | |
| Constellation Pharmaceuticals, Inc | New Therapeutics That Target Epigenetic Regulatory Proteins in Cancer | $ 244,479.25 | |
| CorNova Inc | The FiberHalo Catheter | $ 244,479.25 | |
| Correx Inc | Correx 18-mm Aortic Valve Bypass Kit | $ 244,479.25 | |
| Creagen Biosciences, Inc | Anticancer agents based on a dual function structures | $ 205,841.50 | $ 38,637.74 |
| Curaxis Pharmaceutical Corporation | ALADDIN Clinical Trials | $ 39, 154.00 | |
| CuriRx Inc | Novel anti-cancer drug candidate | $ 15,410.00 | $ 109,750.00 |
| Curis Inc | Multi-targeted network inhibitor platform for cancer | $ 244,479.25 | |
| Curis, Inc | CUDC-101, a Phase 1 cancer agent | $ 244,479.25 | |
| CYTOCURE LLC | Novel Combination Immunotherapy of Cancer: Drugs that Enhance Tumor Antigens | $ 120,224.00 | $ 124,255.25 |
| Cytonome/ST, LLC | Therapeutic Cell Sorter for Blood Cancers | $ 244,479.25 | |
| CytoVera Inc | High Potency Cord Blood Stem Cells as Therapeutics for Treatment for Treating Blood Cancers in Adults. | $ 7,926.50 | $ 125,000.00 |
| Daktari Diagnostics Inc. | Development of a Handheld CD4 Cell Counter for Point-of-Care Monitoring of HIV Patients | $ 244,479.24 | |
| Dicerna Pharmaceuticals Inc | A Novel Castration Restitant Prostate Cancer Treatment Targeting Androgen Receptor | $ 244,479.24 | |
| Dicerna Pharmaceuticals Inc | Dicer Substrate Technology ™, a new and novel RNAi-based drug development platform | $ 244,479.24 | |
| Differential Proteomics, Inc. | Antibody Repertoire Profiling for Enabling Detection, Diagnosis and Treatment of Diseases | $ 132,836.84 | $ 111,642.41 |
| DNA Medicine Institute, Inc. | Universal Blood Sensor | $ 54,048.50 | $ 168,950.00 |
| Dragonfly Sciences, Inc | Etanercept Biosimilar | $ 244,479.25 | |
| Dune Medical Devices Inc | MarginProbe System | $ 244,479.25 | |
| Dyax Corp | FcRn (DX-2500) | $ 220,011.50 | $ 24,467.75 |
| Dyax Corp | DX-88 HAE KALBITOR | $ 244,479.25 | |
| Dyax Corp | DX-2400 | $ 244,479.25 | |
| Dyax Corp | ACE inhibitor Induced Angioedema | $ 179,610.00 | $ 64,869.25 |
| Dyax Corp. | MMP-9 (DX-2802) | $ 244,479.25 | |
| Dyax Corp. | Plasma Kallikrein Inhibitor | $ 244,479.25 | |
| EarthGenes Pharmaceuticals LLC | Antibiotic Drug Discovery from Environmental DNA Expression Libraries | $ 69,882.50 | $ 166,689.50 |
| Echo Therapeutics, Inc | Symphony Transdermal Continuous Glucose Monitoring System | $ 244,479.25 | |
| ECW Therapeutics, Inc | Adults & Neonatal Stem Cell Seperation Device | $ 80,000.00 | |
| Edimer Pharmaceuticals | EDI200, a recombinant protein for treatment of X-linked hypohidrotic ectodermal dysplasia. | $ 244,479.24 | |
| Eleven Biotherapeutics Inc | Protein based drug discovery project Myostatin for Muscle wasting | $ 244,479.25 | |
| Eleven Biotherapeutics, Inc. | Protein-based drug discovery project: T helper cell, 17 in inflammatory diseases | $ 244,479.25 | |
| Eleven Biotherapeutics, Inc. | Protein-based drug discovery project: Factor VIII for the treatment of Hemophilla A | $ 244,479.25 | |
| Elixir Pharmaceuticals, Inc | Development of a Small Molecule Ghrelin Antagonist, EX-1832, for the Treatment of Metabolic Disorders | $ 244,479.25 | |
| Enanta Pharmaceuticals Inc | Novel Oral Antibiotic for the treatment of MRSA, VRE and Resistant Strep Infections | $ 211,295.50 | |
| Enanta Pharmaceuticals Inc | Novel NS5A Inhibitors for the treatment of Hepatitis C Infection | $ 49,673.00 | |
| Enanta Pharmaceuticals Inc. | Novel I.V. Antibiotic for the treatment of MRSA, VRE and resistant Strep Infections | $ 49,673.00 | |
| Enanta Pharmaceuticals, Inc | Novel Cyclophilin inhibitors for the Treatment of Hepatitis C Infection | $ 244,479.24 | |
| Endra Inc | Thermoacoustic imaging device for point of care diagnosticapplications | $ 129,189.02 | $ 115,290.23 |
| Energesis Pharmaceuticals Inc | Discovery of Novel Brown Fat Targeting Drugs for Obesity | $ 244,479.24 | |
| Enlight Biosciences, LLC | Enigma Liver Toxicity | $ 41,214.64 | $ 79,990.33 |
| Enlight Biosciences, LLC | Ensof Biomarker Discovery | $ 27,992.37 | $ 216,486.88 |
| Enlight Biosciences, LLC | Entrega Drug Delivery | $ 118,888.34 | $ 125,590.91 |
| Ensemble Therapeutics Corporation | DNA-Programmed Chemistry and its Application for the Discovery of Novel Oncology Drugs. | $ 244,479.24 | |
| Ensemble Therapeutics Corporation | New Personalized Medicine Diagnostics for Predicting Drug Resistance in Breast Cancer | $ 244,479.24 | |
| Ensemble Therapeutics Corporation | Oral Macrocycle Drugs for Treatment of Rheumatiod Arthritis & Other Inflammatory Diseases. | $ 244,479.24 | |
| Entra Pharmaceuticals Inc | Novel Biopharmaceuticals Drug Delivery System | $ 244,479.25 | |
| Epizyme Inc | WHSC1 Therapeutic Project | $ 244,479.24 | |
| Epizyme Inc | DOT1L Therapeutic Project | $ 244,479.24 | |
| Epizyme Inc | EZH2 Therapeutic Project | $ 244,479.24 | |
| ETEX Corporation | Bone Regenerating Biomaterial | $ 244,479.24 | |
| Euthymics Bioscience, Inc | EB-1020: A novel treatment for adult Attention Deficit Hyperactivity Disorder (ADHD) | $ 5,802.50 | $ 238,676.75 |
| Euthymics Bioscience, Inc. | EB-1010: A NOVEL ANTIDEPRESSANT TO PATIENTS NOT RESPONDING ADEQUATELY TO SSRIs | $ 52,224.00 | $ 192,255.25 |
| Eutropics Pharmaceuticals | Developing BH3 profiling as a predictive diagnostic test for multiple myeloma | $ 32,910.50 | $ 105,652.50 |
| Eutropics Pharmaceuticals | Developing Small molecule inhibitor of Mcl-1to treat blood cancer | $ 78,719.00 | $ 165,760.25 |
| Excelimmune Inc. | Development and Manufacture of Human Recombinant Polyclonal Antibodies (HRPA) | $ 244,479.24 | |
| Eyegate Pharmaceuticals Inc | Biologics | $ 56,500.00 | $ 173,500.00 |
| EyeGate Pharmaceuticals Inc | Nanoparticles | $ 174,500.00 | $ 69,979.25 |
| Eyegate Pharmaceuticals Inc | EGP 437 | $ 244,479.25 | |
| Eyegate Pharmaceuticals, Inc | EyeGate III | $ 244,479.25 | |
| Fifth Base, LLC | Prevention of Tumor Recurrence via Flexible Chemotherapy-Eluting Strips | $ 55,799.14 | $ 22,539.94 |
| First Light Biosciences, Inc | Novel low-cost automated platform for rapid and sensative detection of resistant bacteria | $ 244,479.25 | |
| Flexion Therapeutics Inc | FX005 Intra-articular Injection for Treatment of Pain in Osteoarthritis of the Knee | $ 244,479.25 | |
| Flexion Therapeutics, Inc. | FX004- Acamprosate for the Treatment of Tinnitus | $ 137,784.50 | $ 106,694.75 |
| FoldRx Pharmaceuticals | Tafamidis for the treatment of TTR Amyloidosis | $ 244,479.25 | |
| Forma Therapeutics, Inc | Unduggable Targets Important for Cancer Treatment (Protein/Protein Interactions) | $ 244,479.25 | |
| Forma Therapeutics, Inc | NAMPT | $ 244,479.25 | |
| Forma Therapeutics, Inc | Diversity-Oriented Synthesis (DOS) Chemistry | $ 244,479.25 | |
| Formatech Inc | Miradocetaxel Development | $ 15,635.50 | $ 113,901.50 |
| Foundation Medicine, Inc. | Molecular Cancer Diagnostics | $ 244,479.25 | |
| Galenea Corp. | 5-HT6 Antagonists for cognitive improvement in schizophrenia | $ 65,651.00 | $ 178,828.25 |
| GALENEA CORP. | 5-HT2C Agonists for Appetite Suppression in Obesity | $ 244,479.25 | |
| Galenea Corp. | Discovery of novel mechanism-based therapies for Schizophrenia | $ 244,479.25 | |
| Gelesis Inc | Gelesis Novel Hydrogels | $ 244,479.25 | |
| Gene Network Sciences, Inc | Collaboration with Biogen Idec Phase I | $ 28,457.50 | |
| Genetix Pharmaceuticals Inc | Lentiglobin | $ 244,479.24 | |
| Genetix Pharmaceuticals Inc | Lenti-D | $ 244,479.24 | |
| Genocea Biosciences, Inc | Development of a Chlamydia Vaccine Based on Natural Immunity in Humans | $ 244,479.24 | |
| Genocea Biosciences, Inc. | Development of Vaccines for Genital Herpes Based on Natural Immunity in Humans | $ 244,479.24 | |
| GI Dynamics, Inc. | The EndoBarrier for treatment of type 2 diabetes and obesity | $ 244,479.25 | |
| GLSynthesis Inc | Hybrid Molecules Designed to Enhance Antibiotic Activity | $ 244,479.24 | |
| GLSynthesis Inc. | Novel drugs to treat Urinary Incontinence | $ 244,479.24 | |
| GLSynthesis Inc. | Preclinical development of a novel antibacterial for Clostridium difficile disease | $ 219,164.00 | |
| GLSynthesis Inc. | Novel Antithrombotic Diadenosine Tetraphosphate Analogs | $ 151,747.00 | $ 92,732.24 |
| GLSynthesis, Inc. | Rapid in vitro Substrate Assay for the multi-drug Resistant P-glycoprotein | $ 107,992.00 | $ 132,649.50 |
| Glycosyn, Inc. | Oligosaccharides to Prevent Infectious Diarrhea | $ 155,208.00 | $ 89,271.24 |
| Good Start Genetics | GSG Molecular Genetic Screen Platform | $ 145,925.39 | $ 98,553.86 |
| Grove Instruments Inc | Nonivasive glucose monitor for diabetic patients | $ 244,479.25 | |
| Healthrageous, Inc. | SmartHealth: Hypertension Self-Management | $ 244,479.25 | |
| Helicos BioSciences Corporation | Non-invasive detection of genetic disorders for prenatal diagnostics | $ 138,671.50 | $ 93,884.50 |
| Helicos BioSciences Corporation | Identification of disease-specific mutations and polymorphisms in affected individuals | $ 244,479.25 | |
| Helicos BioSciences Corporation | Detection of pathogen nucleic acid contamination in body fluids & in biological therapeutics | $ 88,828.50 | $ 155,650.75 |
| Hemedex, Inc. | Novel Device to Diagnose Conditions of Compromised Blood Flow and to Quantify Edema | $ 244,479.25 | |
| Highland Instruments | Electrosonic Stimulation for Noninvasive deep Brain Stimulation | $ 47,534.00 | $ 68,890.00 |
| Histogenics Corporation | NeoCart (Cultured Autologous Neo-Cartilage) | $ 244,479.24 | |
| Hybrid Silica Technologies Inc | Multimodal Silica Nanoparticles as Cancer Targeted Probes for Clinical Translation | $ 228,130.00 | $ 16,349.25 |
| Hydra Biosciences, Inc | TRPA1 Antagonists as a Broad Medical Countermeasure to Biological and Chemical Threats | $ 200,753.50 | $ 43,725.74 |
| Hydra Biosciences, Inc. | TRPA1 Antagonists as New Treatments for Pain due to injury or inflamation | $ 244,479.24 | |
| Hydra Biosciences, Inc. | TRPV3 Antagonists as New Treatments for Chronic and Acute Pain | $ 244,479.24 | |
| ImmuneXcite, Inc | A unique Herceptin conjugate directs neutrophils to fight breast cancer | $ 42,352.50 | $ 68,737.50 |
| ImmunoDiagnostics, Inc | Jak2/Hexim1 kinase inhibitors as therapeutics for the treatment of viral (HIV) disorders | $ 107,730.00 | $ 136,749.25 |
| ImmunoGen Inc | IMGN009- Antibody-drug conjugate to fight cancer | $ 244,479.24 | |
| ImmunoGen Inc. | IMGN007 Antibody-drug conjugate to fight cancer. | $ 153,250.00 | $ 91,229.24 |
| ImmunoGen Inc. | IMGN529 Antibody-drug conjugate. | $ 244,479.24 | |
| ImmunoGen Inc. | IMGN388 antibody-drug conjugate | $ 244,479.24 | |
| ImmunoGen, Inc. | Lorvotuzumab mertansine - IMGN901 - antibody-drug conjugate | $ 244,479.24 | |
| Inanovate Inc | Development of a low-cost, accurate cancer diagnostic platform. | $ 227,192.05 | $ 17,287.19 |
| InaVein, LLC | Office-based Varicose Vein Treatment with Local Anesthesia | $ 38,494.50 | |
| Infinity Discovery, Inc | Hsp90 Chaperone Inhibitor Program | $ 244,479.24 | |
| Infinity Discovery, Inc | IPI 926 Hedgehog Pathway Inhibitor Program | $ 244,479.25 | |
| Infinity Discovery, Inc | IPI-940 Fatty acid Amide Hydrolase Inhibitor Program | $ 244,479.25 | |
| InfraReDx, Inc | Clinical validation of near-infrared spectoscopy for diagnosing high risk coronary plaques | $ 244,479.25 | |
| InfraReDx, Inc | LipiScan ™ IVUS Diagnostic System | $ 244,479.25 | |
| InnerSea Technology Inc | Early Warning System for Spinal Cord injured at Risk for Autonomic Dysreflexia | $ 103,489.50 | $ 106,677.00 |
| Inotek Pharmaceuticals Corporation | INO-8875 | $ 244,479.24 | |
| Inotek Pharmaceuticals Corporation | Development of PARPs for use in oncology treatment | $ 178,152.67 | $ 66,326.58 |
| Inotek Pharmaceuticals Corporation | INO-4885 | $ 182,507.61 | $ 27,493.59 |
| Intact Medical Corp | Breast Lesion Excision System | $ 244,479.24 | |
| Intelect Medical, Inc. | Novel Programming Device to Further the Delivery of Deep Brain Stimulation Devices | $ 244,479.25 | |
| Intelligent Bio-Systems | DNA Sequence Based Cancer Diagnostic System | $ 244,479.25 | |
| Intelligent Medical Devices Inc | XMRV and other molecular factors to assess prostate cancer | $ 11,214.00 | $ 96,384.50 |
| Intelligent Medical Devices Inc | Low Cost Screening for Healthcare Associated infections | $ 209,418.00 | $ 35,061.25 |
| Intelligent Medical Devices Inc | Detection and Resistance Screening for Influenza | $ 244,479.25 | |
| Intelligent Medical Devices, Inc | Monitoring Viruses Associated with Transplant Rejection | $ 117,346.50 | $ 73,475.50 |
| Intelligent Medical Devices, Inc. | Comprehensive Test to Guide Treatment and Prevent Outbreaks of Whooping Cough | $ 97,308.50 | $ 147,170.75 |
| Interlace Medical, Inc | MyoSure Rod Lens Hysteroscope Development Project | $ 244,479.25 | |
| Interleukin Genetics | Osteoarthritis | $ 128,071.00 | $ 100,843.50 |
| Interleukin Genetics Inc | Perilipin | $ 227,377.00 | $ 17,102.25 |
| InVivo Therapeutics Corporation | Safety and Efficacy of an Implanted Biodegradable Polymeric Scaffold to Treat Spinal Cord injury | $ 244,479.25 | |
| IQuum, Inc | Rapid Point of Care Molecular Diagnostics for Influenza; Seasonal & Pandemic H1N1 Assays | $ 244,479.25 | |
| Iquum, Inc. | Rapid, Point of Care Molecular Diagnostic Assay for Detection of Fungemia | $ 76,541.00 | $ 167,938.25 |
| Ironwood Pharmaceuticals Inc | Development of Novel CRTH2 Inhibitor, IW-1221, for Treatment of Asthma | $ 244,479.25 | |
| Ironwood Pharmaceuticals Inc | FAAH Inhibitor, IW-6118 to Treat Pain and Inflammation | $ 244,479.25 | |
| Ironwood Pharmaceuticals, Inc | Linaclotide, A Novel Guanylate Cycase C Agonist | $ 244,479.25 | |
| Ironwood Pharmaceuticals, Inc. | IW-9179, for Treatment of Gastroparesis and Functional Dyspepsia. | $ 180,000.00 | $ 64,479.25 |
| Ischemix LLC | CMX-2043 | $ 244,479.24 | |
| Jasco Pharmaceuticals, LLC | The Pim Inhibitor Project | $ 244,479.24 | |
| JB Therapeutics Inc | Clinical Development of an oral, non-psychotropic CB1/CB2 Cannabinoid Agonist for the treat Chronic Pain | $ 19,587.50 | $ 224,891.75 |
| JEF Core, Incorporated | Development of a Lead Based System for Respiratory Variation Monitoring | $ 41,392.00 | $ 160,749.50 |
| Kala Pharmaceuticals, Inc. | Development of KALA617, a once-daily inhalable b-lactam to treat Cystic Fibrosis infections | $ 12,500.00 | $ 231,979.24 |
| KARYOPHAM THERAPEUTICS | NOVEL CRM1 INHIBITORS FOR THE TREATMENT OF CANCER | $ 92,500.00 | $ 151,979.25 |
| Ligon Discovery Inc | Development of HIF inhibitors for Renal Cell Carcinoma | $ 244,479.25 | |
| Link Medicine Corporation | LNK-3248: Treating Alzheimer's Disease by Clearing Toxic Proteins | $ 63,348.00 | $ 181,131.25 |
| Link Medicine Corporation | LNK-754 Enhancing Autophagy and Mitochondrial Function to Treat Alzheimer's Disease | $ 244,479.25 | |
| Link Medicine Corporation | LNK-3186: Developing Novel Treatments for Alzheimer's Disease | $ 166,439.00 | $ 78,040.25 |
| LOGICAL THERAPEUTICS, INC | LT-NS001 (NAXPROXEN ETEMESIL) | $ 244,479.25 | |
| Lubris LLC | Prevention and Treatment of Osteoarthritis | $ 23,550.00 | |
| Marine Polymer Technologies Inc | Development of Novel Biomaterial for Trauma Hemorrhage, Diabetic, & Infected Wound Care | $ 201,000.50 | $ 43,478.75 |
| Marine Polymer Technologies Inc | Development of IL-15 Protein Complex as a Therapy for Lymphopenia & Cancer | $ 79,633.00 | $ 45,878.00 |
| MC10, Inc. | Conformal Electronics for Diagnosing and Treating Heart Disease | $ 204,079.79 | $ 40,399.46 |
| Medical Discovery Partners LLC | A Blood Test for the Early Detection of Cancer | $ 60,887.00 | $ 163,617.50 |
| Medwell Foods, Inc | Medwell 1-2-3 Molecular Baking | $ 244,479.25 | |
| Mercator Therapeutics, Inc. | The Tumor Targeting Project | $ 244,479.25 | |
| Mercury Therapeutics, Inc | Development of Direct AMP Kinase Activators for Type 2 Diabetes | $ 184,696.97 | $ 59,782.28 |
| Merrimack Pharmaceuticals Inc | MM-151 | $ 244,479.24 | |
| Merrimack Pharmaceuticals Inc | MM-141 | $ 244,479.24 | |
| Merrimack Pharmaceuticals Inc | MM-121 | $ 244,479.24 | |
| Merrimack Pharmaceuticals Inc | MM-302 | $ 244,479.24 | |
| Merrimack Pharmaceuticals Inc | MM-111 | $ 244,479.24 | |
| Merrimack Pharmaceuticals Inc. | MM-POD2 | $ 184,931.50 | $ 59,547.74 |
| Merrimack Pharmaceuticals, Inc | MM-POD3 | $ 86,698.50 | $ 157,780.74 |
| Merrimack Pharmaceuticals, Inc | MM-131 | $ 244,479.24 | |
| Merrimack Pharmaceuticals, Inc. | MM-POD1 | $ 193,380.50 | $ 51,098.74 |
| Merrimack Pharmaceuticals, Inc. | MM-398 | $ 9,228.50 | $ 235,250.74 |
| Mersana Therapeutics Inc | XMT-1001 | $ 244,479.25 | |
| Mersana Therapeutics Inc | siRNA | $ 244,479.25 | |
| Mersana Therapeutics, Inc | XMT-1107 | $ 244,479.25 | |
| Metamark Genetics Inc | Development of function-based prognostic assays to optimize and personalize cancer care | $ 244,479.24 | |
| Microbiotix | Preclinical development of antagonists of host immunity | $ 9,586.88 | $ 10,187.29 |
| Microbiotix, Inc | Preclinical development of bacterial replication inhibitors | $ 244,479.24 | |
| Microbiotix, Inc | Preclinical Inhibitors of Botulinum Neurotoxin A | $ 244,479.24 | |
| Microbiotix, Inc | Preclinical development of novel anti-biofilm coatings for implanted medical devices | $ 15,526.04 | $ 64,817.83 |
| Microbiotix, Inc | Preclinical development of novel broad-spectrum hemorrhagic fever virus inhibitors | $ 118,957.83 | $ 125,521.41 |
| Microbiotix, Inc. | Clinical development of MBX400: a novel inhibitor of human cytomegalovirus infection | $ 244,479.24 | |
| Microbiotix, Inc. | Preclinical inhibitors of non-replication essential bacterial targets | $ 244,479.24 | |
| Microbiotix, Inc. | Preclinical Inhibitors of bacterial virulence factors | $ 160,378.98 | $ 84,100.26 |
| MicroCHIPS Inc | Development of an implantable one year Continuous Glucose Monitoring System | $ 244,479.25 | |
| MicroCHIPS Inc | Development of an implantable drug delivery device controlled release of PTH for one year | $ 244,479.25 | |
| MindChild Medical Inc | Meridian Monitor | $ 111,795.00 | $ 132,684.24 |
| MINERVA BIOTECHNOLOGIES CORP | THERAPEUTIC DISABLES PRIMAL GROWTH MECHANISM ON CANCER STEM CELLS | $ 244,479.24 | |
| Mobius Imaging LLC | SurgiTom | $ 244,479.25 | |
| Modular Genetics, Inc. | Biosynthetic Meridamycin Analogs for Neurological Disorders | $ 170,718.50 | $ 73,760.75 |
| MOLECULAR INSIGHT PHARMACEUTICALS INC | ZEMIVA | $ 244,479.25 | |
| Molecular Insight Pharmaceuticals Inc | Trofex | $ 244,479.25 | |
| MOLECULAR INSIGHT PHARMACEUTICALS INC | SOLAZED | $ 211,316.50 | $ 33,162.75 |
| Molecular Insight Pharmaceuticals, Inc | Azedra - Neuroblastoma | $ 244,479.25 | |
| Molecular Insight Pharmaceuticals, Inc. | Azendra - Pheochromocytoma | $ 244,479.25 | |
| Molecular Insight Pharmaceuticals, Inc. | Onalta | $ 244,479.25 | |
| Momenta Pharmaceuticals, Inc | M118, a novel antigoagulant to treat patients diagnosed with Acute Coronary | $ 244,479.25 | |
| Momenta Pharmaceuticals, Inc | Platform for Glycosaminoglycan Therapeutics-Novel Multimodal Drugs for Multifaceted diseases | $ 244,479.25 | |
| Momenta Pharmaceuticals, Inc | M402- A novel multimodal inhibitor of tumor metastasis | $ 244,479.25 | |
| Momenta Pharmaceuticals, Inc | Development of a biologics platform utilizing through characterization to ensure purity | $ 244,479.25 | |
| Nano Surfaces, Inc. | Drug Delivery Micelles | $ 244,479.25 | |
| Nanobiosym Diagnostics | Gene-RADAR for Medical Molecular Diagnostics | $ 72,164.00 | $ 172,315.24 |
| Nanobiosym, Inc | Single Molecule Drug Discovery | $ 244,479.24 | |
| NetBio, Inc | Rapid Nucleic Acid-Based Diagnosis of STDs at the Point-of -Care | $ 244,479.24 | |
| NeurAxon (USA) Inc. | NXN-462 for chronic daily headache and post-herpetic neuralgia | $ 42,011.00 | $ 202,468.24 |
| NeurAxon (USA), Inc. | NXN-188 for acute migraine | $ 244,479.24 | |
| NeuroHealing Pharmaceuticals, Inc. | NH001 | $ 180,467.50 | $ 64,011.75 |
| Neurometrix Inc | Precision Targeted Therapeutic Delivery System for Peripheral Nerve Indications | $ 244,479.24 | |
| Neuron Systems, Inc | Development of a definitive treatment for dry amd and stargardt's diesease | $ 244,479.25 | |
| NeuroPhage Pharmaceuticals, Inc. | NPT001, a novel disease-modifying treatment for Alzheimer's Disease | $ 244,479.25 | |
| Neuroptix Corporation | Ocular Diagnostic Test for Alzheimer's Disease | $ 244,479.24 | |
| Nextcea, Inc. | Diagnosis and Therapy of Drug-Induced Phospholipidosis and of Niemann-Pick Diseases | $ 66, 107.24 | |
| Nikan Pharmaceuticals, LLC | Development of Novel Compounds for Treatment of Inflammatory Disorders in Humans | $ 6,333.50 | $ 2,855.00 |
| Nimbus Apollo, Inc. | Preclinical R&D to advance lead molecules targeting ACC for obesity and diabetes | $ 196,019.50 | |
| Nimbus Discovery Inc | R&D to advance programs targeting PFKFB3 and ZAP70 kinases for cancer & inflammation | $ 71,412.50 | $ 173,066.75 |
| Nimbus Iris Inc | Preclinical R&E to advance lead molecules targeting IRAK4 for inflammatory disease | $ 244,479.25 | |
| NinePoint Medical, Inc. | N-lighten Optical Diagnostic and Therapeutic System | $ 244,479.25 | |
| NKT Therapeutics INC | Development of Antibodies Directed Towards NKT Cells | $ 244,479.24 | |
| NormOxys, Inc | Development of OXY111A for the Treatment of Cancer and Cardiovascular Disease | $ 244,479.25 | |
| Novelos Therapeutics, Inc. | NOV-002 Development | $ 244,479.25 | |
| Nuclea Biotechnologies LLC | Therapeutic Diagnostic/Prognostic Assay Development Program | $ 244,479.25 | |
| Nuclea Biotechnologies, LLC | Research Methodology for Therapeutic/Diagnostic Discovery | $ 228,990.00 | $ 15,489.25 |
| Nuclea Biotechnologies, LLC | Humanized Anti-Cancer Monoclonal Antibodies | $ 79,104.00 | $ 165,375.25 |
| Ocular Therapeutix, Inc | Epi-Coat | $ 132,373.00 | $ 112,106.24 |
| Ocular Therapeutix, Inc. | ReSure Adherent Ocular Bandage | $ 244,479.25 | |
| Ocular Therapeutix, Inc. | Punctum Drug Depot | $ 244,479.25 | |
| On-Q-ity Inc. | Breast Biopsy Tumor Tissure test to predict response to anthracycline treatment | $ 244,479.25 | |
| On-Q-ity Inc. | Lung Biomarker Tumor Tissue test to predict cisplatin response in lung cancer patients | $ 200,422.50 | $ 44,056.75 |
| On-Q-ity Inc. | HER-2 Circulating Tumor Cell test to inform therapeurtic choice for breast cancer patients | $ 93,187.00 | $ 151,292.25 |
| On-Q-ity Inc. | EGFR circulating tumor cell test to inform therapeutic choice for lung cancer patients | $ 86,661.50 | $ 157,817.75 |
| OPK Biotech LLC | HBOC-201/cGMP Manufacturing Facility | $ 244,479.25 | |
| ORA, Inc | Novel Immunotherapy Treatment for Dry AMD | $ 99,743.00 | $ 144,736.25 |
| ORA, Inc | Novel Cerumenolytic | $ 31,599.50 | $ 18,486.00 |
| ORA, Inc | Novel Anti-Allergic | $ 191,293.50 | $ 53,185.75 |
| ORA, Inc | Novel Nasal Treatment for MRSA | $ 90,844.50 | $ 142,004.50 |
| Orban Biotech LLC | Insulin B Chain to Treat Type 1 Diabetes Mellitus | $ 244,479.25 | |
| Orbital Therapy, LLC | Self-shielding radiotherapy device | $ 244,479.24 | |
| Ore Pharmaceutical Holdings Inc | ORE1001 | $ 244,479.25 | |
| PAKA Pulmonary Pharmaceuticals Inc | SP-B-Polymyxin Conjugate For Lung Infection | $ 34,230.00 | |
| Paloma Pharmaceuticals, Inc | Palomid 529, a First -in-Class Dual TORC 1/2 Inhibitor of the P13k/Akt/m TOR Pathway | $ 244,479.24 | |
| Paratek Pharmaceuticals Inc | Development of Oral Therapies for Major Chronic AutoImmune Diseases: MS, RA, IBD | $ 244,479.25 | |
| Paratek Pharmaceuticals, Inc | Gram-Negative Hospital Bacterial Infections; Treatment and Prophylaxis | $ 244,479.25 | |
| Paratek Pharmaceuticals, Inc | PTK 0796- A First-in-Class Oral & IV antiboiotic in Phase 3 for Serious Infections, incl. MRSA | $ 244,479.25 | |
| Pear Tree Pharmaceuticals, Inc | Treatment of Moderate to Severe Vulvar and Vaginal Atrophy in Menopausal Patients | $ 152,775.40 | $ 91,703.85 |
| Peptimmune, Inc. | PI-2301 for thre ftreatment of Relapsing and Remitting Multiple Sclerosis (RRMS) | $ 244,479.25 | |
| Pervasis Therapeutics, Inc | Development of PVS-10200 for Peripheral Artery Disease | $ 244,479.25 | |
| Pervasis Therapeutics, Inc. | Development of Vascugel® to Sustain Arteriovenous Access for Hemodialysis | $ 244,479.25 | |
| Pervasis Therapeutics, Inc. | Development of Tissue-Engineered Endothelial Cell Therapy for Brain and Prostate Cancer | $ 30,307.90 | $ 161,113.04 |
| Pervasis Therapeutics, Inc. | Devel. Of Tissue-Engineered Endothelial Cell Therapy to Supplement Orthopedic Procedures | $ 35,022.33 | $ 209,456.92 |
| PGxHealth LLC | Vilazodone: A novel treatment for major depressive disorder | $ 244,479.25 | |
| PGxHealth LLC | Apadenoson: A novel pharmacologic stress agent for myocardial perfusion imaging | $ 244,479.25 | |
| Pharmalucence, Inc | Lymph Node Localization by Tc-99m Sulfur Colloid Injection | $ 85,732.00 | $ 158,747.24 |
| Phase Design Research | CNS penetrating anti-inflammatory/metal chelators for treating neuroinflammation | $ 29,921.79 | $ 37,500.00 |
| Physical Sciences Inc | Continuous Automated Mandibular Distractor | $ 71,626.00 | $ 166,094.50 |
| Physical Sciences Inc. | Breath Test for Cancer Therapy | $ 106,900.50 | $ 137,578.75 |
| Physical Sciences Inc. | Dosimeters for Photodynamic Cancer Therapy (PDT) | $ 242,635.00 | $ 1,844.24 |
| Physical Sciences Inc. | Image-Guided Intervention for Pancreatic Cysts | $ 128,383.00 | $ 116,096.25 |
| Physical Sciences, Inc | Retinal Imaging for Disease Detection | $ 244,479.24 | |
| PLC Medical Systems Inc | RenalGuard: A Novel Therapy to Prevent Contrast Induced Nephropathy | $ 244,479.25 | |
| Predictive Biosciences, Inc. | Bladder Cancer Recurrence Monitoring Triage Test | $ 244,479.25 | |
| Predictive Biosciences, Inc. | Test for Prognosis of Bladder Cancer | $ 244,479.25 | |
| Pressure BioSciences, Inc. | Pressure Cycling Technology | $ 244,479.25 | |
| PrimeraDx, Inc. | ViraQuant: Automated Quantitative Multi-Plex Viral Load Assay System | $ 244,479.25 | |
| Privo Technologies | Insulin Chewing Gum | $ 4,000.00 | |
| Pro-Pharmaceuticals, Inc. | Treatment and reversal of liver fibrosis using galectin blockers GRGs | $ 10,083.67 | $ 234,395.57 |
| Pro-Pharmaceuticals, Inc. | Anticancer treatments using galectin blockers combined with chemotherapies or biologics. | $ 244,479.24 | |
| Proteon Therapeutics, Inc. | PRT-201 for Vascular Access in Chronic Hemodialysis Patients | $ 244,479.24 | |
| Provasculon, Inc | Modified SDF-1 for the treatment of myocardial infarct and ischemic tissue | $ 244,479.25 | |
| Provenance Biopharmaceuticals Corp | DI-Leu16-IL2 Anti-cancer Therapeutic | $ 33,421.77 | $ 211,057.48 |
| Provenance Biopharmaceuticals Corp | Veterinary immunocytokines to aid development of therapies for treatment of human cancers | $ 29,117.77 | $ 131,895.54 |
| pSivida US Inc | Sustained Release Brimonidine | $ 110,062.00 | |
| pSivida US, Inc. | Antibodies for Treatment of Wet-Acute Macular Degeneration (Wet-AMD) | $ 98,087.00 | |
| Pulmatrix Inc. | Inhaled Cationic Lining Modulators for Treatment and Prevention of Pulmonary Disease | $ 244,479.25 | |
| Pulsar Clinical Technologies | Multiplex Microarray for Pre-Type 1 Diabetes Autoantibodies | $ 65,183.30 | $ 54,437.03 |
| PureTech Ventures, LLC | Inflammatory Bowel Disease (IBD) | $ 76,490.76 | $ 164,028.87 |
| PureTech Ventures, LLC | Autism | $ 60,835.08 | $ 86,590.68 |
| PureTech Ventures, LLC | Karuna | $ 109,573.80 | $ 134,905.45 |
| Quanterix Corporation | Development of the First Blood-based Diagnostic test for Alzheimer's Disease | $ 244,479.24 | |
| Quanterix Corporation | A TNF-alpha Companion Diagnostic to Predict Response to Therapy in Crohn's Disease | $ 127,716.00 | $ 116,763.24 |
| Quanterix Corporation | Development of a Single Molecule Array Test for Prostate Cancer Recurrence Monitoring | $ 244,479.24 | |
| Radius Health Inc | RAD1901 | $ 244,479.25 | |
| Radius Health Inc | BA058 | $ 244,479.25 | |
| Radius Health, Inc | SARM/RAD140 | $ 244,479.25 | |
| Rapid Micro Biosystems, Inc | Enhanced Robustness of Rapid, Automated Microbial Enumeration | $ 244,479.25 | |
| Reflectance Medical Inc | Non-Invasive Tissue Perfusion for Therapeutic Admin. | $ 101,592.50 | $ 142,886.74 |
| Repligen Corporation | RG3039-DcpS inhibitor for treatment of patients with Spinal Muscular Atrophy (SMA) | $ 201,583.50 | $ 42,895.75 |
| Repligen Corporation | RG2833, an inhibitor of HDAC-3 for the treatment of Friedreich's ataxia | $ 244,479.25 | |
| Repligen Corporation | RG1068 - Synthetic Human Secretin for Pancreatic Imaging | $ 244,479.24 | |
| Resolvyx Pharmaceuticals Inc | DEVELOPMENT OF RESOLVINS TO TREAT Chronic Inflammatory Disease | $ 244,479.24 | |
| RESOLVYX PHARMACEUTICALS, INC | DEVELOPMENT OF RESOLVINS TO TREAT SIGHT-THREATENING DISEASE | $ 244,479.24 | |
| RFE Pharma Corp | RFE-007 CAI injectable for treating diabetic retinopathy & age-related macular degeneration | $ 38,561.00 | $ 92,144.00 |
| Rhythm Pharmaceuticals Inc | Rm-493 | $ 244,479.25 | |
| Rhythm Pharmaceuticals, Inc | RM-131 | $ 244,479.25 | |
| Rxi Pharmaceuticals Corporation | Development of self-delivering RNA Interference (RNAi) therapeutic for the fibrotic disease | $ 244,479.25 | |
| Rxi Pharmaceuticals Corporation | Oral Delivery of Glucose Encapsulated siRNAs for Rheumatoid Arthritis (RA) | $ 244,479.25 | |
| Rxi Pharmaceuticals Corporation | Self-Delivering RNA Interference Therapeutic for Age-Related Macular Degeneration (AMD) | $ 66,002.17 | $ 178,477.08 |
| Rxi Pharmaceuticals Corporation | Self-Delivering RNA Interference Therapeutic for ALS (Lou Gehrig's Disease) | $ 237,273.92 | $ 7,205.33 |
| Satori Pharmaceutcals Incorated | Gamma-Secretase Modulators for the treatment of Alzheimer's Disease | $ 244,479.24 | |
| SBH Sciences Inc | Development of a Therapy for Liver Fibrosis by Specific Targeting of Galectin-3 | $ 98,932.50 | $ 112,000.00 |
| SBH Sciences, Inc | Developing Therapy for Pancreatic Cancer Targeting Nuclear Export by CRM-1 | $ 44,600.00 | $ 140,100.00 |
| Sci Dose LLC | Ulcerative Colitis | $ 188,828.00 | $ 55,651.25 |
| SciDose, LLC | Docetaxel | $ 244,479.25 | |
| Seahorse Bioscience, Inc | Prevention and treatment of age-related diseases by targeting defects in mitochondria. | $ 244,479.25 | |
| Seahorse Bioscience, Inc. | Diagnosis of Metabolic and Age-Related Diseases | $ 244,479.25 | |
| Seaside Therapeutics Inc | Development of Arbaclofen (STX209) for the Treatment of Fragile X Syndrome | $ 244,479.25 | |
| Seaside Therapeutics Inc, | Development of Novel M1 Modulators for the Treatment of Austism and Fragil X syndrome | $ 244,479.25 | |
| Seaside Therapeutics Inc. | Discovery Project to identify biomarkers related Austism Spectrum Disorders(ASD) | $ 244,479.25 | |
| Seaside Therapeutics, Inc. | Development of mGluR5 Modulators for the Treatment of Autism and Fragile X Syndrome | $ 244,479.25 | |
| Seaside Therapeutics, Inc. | Development of STX107 for the Treatment of Fragile X Syndrome | $ 244,479.25 | |
| Seaside Therapeutics, Inc. | Development of Arbaclofen (STX209) for the Treatment of Autism Spectrum disorders (ASD) | $ 244,479.25 | |
| Selecta Biosciences, Inc | Nicotine Vaccine for Smoking Cessation and Relapse Prevention | $ 244,479.25 | |
| Selecta Biosciences, Inc | A synthetic Nanoparticle Vaccine Platform to induce a Cytolytic T-Cell Response | $ 244,479.24 | |
| Selecta Biosciences, Inc. | Development of a Synthetic Nanoparticle Vaccine Platform to Induce Protective Antibodies | $ 244,479.25 | |
| SelectX Pharmaceuticals Inc | SXP2554: A Novel Inhaled Antibiotic | $ 244,479.25 | |
| SelectX Pharmaceuticals, Inc. | SXP2523: A Novel Antibiotic for Serious Gram-Negative Infections | $ 244,479.25 | |
| Semaco Inc. | Targeting Telomere-Associated Werner Protein to Treat Hematologic Malignancy | $ 156,500.00 | $ 87,979.24 |
| Semprus BioSciences | Semprus PICC (Peripherally Inserted Central Catheter) | $ 244,479.25 | |
| Sentien Biotechnologies, Inc. | Stem Cell Therapeutic Devices for Critical Care | $ 244,479.25 | |
| SetPoint Medical Corporation | Immune System Regulator Therapy | $ 244,479.25 | |
| Seventh Sense Biosystems, Inc. | On Vivo, A Fully Integrated Blood Collection and Diagnostic Test Device | $ 244,479.24 | |
| Shape Pharmaceuticals, Inc. | SHP-141 for the treatment of Cutaneous T-Cell Lymphoma(CTCL) | $ 244,479.25 | |
| SimulConsult, Inc | SimuConsult Diagnostic Decision Support Software | $ 244,479.25 | |
| SmartCells, Inc | SmartInsulin-The First Glucose-regulated insulin for Treating Diabetes | $ 244,479.24 | |
| Soteira, Inc | Soteira Shield Kyphoplasty System | $ 244,479.25 | |
| Speech Technology and Applied Research Corp | Objective Acoustic Speech Analysis for Post Concussional Blast Effects | $ 626.50 | $ 15,329.50 |
| Speech Technology and Applied Research Corp | System for DBS Programming for Speech Functionality in Parkinson's Disease | $ 146,055.50 | $ 98,423.75 |
| Spring Bank Pharmaceuticals, Inc | SB 9000 | $ 244,479.24 | |
| Still River Systems, Inc. | Proton Beam Radiotherapy System (PBRT) | $ 244,479.25 | |
| Strohl Medical Technologies Inc | SEP-RAD Stroke Detection Device | $ 34,975.00 | |
| Stromedix, Inc. | Development of STX-100 as a novel therapeutic for the treatment of fibrotic diseases | $ 244,479.24 | |
| Sunshine Medical LLC | Interactive feeding system for the premature infant | $ 244,479.25 | |
| Surface Logix, Inc | SLx-2119, a small molecule inhibitor of Rho kinase 2 (ROCK2) for oncology and fibrosis | $ 244,479.24 | |
| Surface Logix, Inc | Intestinally selective small molecule activators of satiety | $ 244,479.24 | |
| Surface Logix, Inc | SLx-2101, a small molecule PDES inhibitor targeting cardiovascular disease | $ 244,479.24 | |
| Surface Logix, Inc | SLx-4090 Microsomal Triglyceride Transfer Protein (MTP) | $ 244,479.24 | |
| Surface Logix, Inc | 50 Soldiers Field Place | $ 244,479.24 | |
| Surface Logix, Inc. | Intestinally selective small molecule inhibitors of DGAT for obesity and diabetes | $ 232,867.49 | $ 11,611.75 |
| Synageva BioPharma Corp | Enhancement of the glycosylation machinery of the Synageva Expression Platform | $ 16,995.76 | $ 107,290.28 |
| Synageva BioPharma Corp | SBC-101 | $ 244,479.25 | |
| Synageva BioPharma Corp | SBC-091 | $ 244,479.24 | |
| Synageva BioPharma Corp | SBC-014 | $ 244,479.24 | |
| Synageva BioPharma Corp | SBC-055 | $ 244,479.24 | |
| Synageva BioPharma Corp | SBC-103 | $ 24,026.32 | $ 105,693.33 |
| Synageva BioPharma Corp | SBC-105 | $ 91,706.28 | |
| Synageva BioPharma Corp. | SBC-104 | $ 244,479.25 | |
| Synageva BioPharma Corp. | SBC-102 | $ 244,479.24 | |
| Synageva BioPharma Corp. | SBC-201 | $ 182,911.81 | $ 55,148.08 |
| Synageva BioPharma Corp. | SBC-202 | $ 89,388.76 | $ 47,469.53 |
| Synageva BioPharma Corp. | PTR-302 | $ 101,394.51 | |
| SynapDx Corporation | Retrospective Study and Prospective Trial to Develop Autism Spectrum Disorder Diagnostic | $ 244,479.25 | |
| Syndax Pharmaceuticals Inc | Syndax Pharmaceuticals Entinostat for the Treatment of Breast Cancer and HL | $ 244,479.24 | |
| SynDevRX, Inc | High potency polymer/metAP2 inhibitors for the treatment of cancer | $ 216,825.00 | $ 27,654.24 |
| Syndexa Pharmaceuticals Corp | ISR Modulators as Novel Drugs for the Treatment of Type 2 Diabetes and Metabolic Diseases | $ 244,479.24 | |
| Syndexa Pharmaceuticals Corp. | Novel Bivalent JNK Modulators for the Treatment of Obesity and Type 2 Diabetes | $ 244,479.24 | |
| Synovex Corporation | SDP051 is a Cad-11 antagonist antibody for the treatment of rheumatoid arthritis | $ 244,479.25 | |
| Synta Pharmaceuticals Corp | Development of elesclomol as a cancer therapeutic | $ 244,479.24 | |
| Synta Pharmaceuticals Corp | Development of a novel, small molecule Hsp90 inhibitor, STA-9090, as a cancer therapeutic | $ 244,479.24 | |
| Synta Pharmaceuticals Corp. | Oral CRAC channel inhibitor therapeutics for inflammatory diseases and cancer | $ 244,479.25 | |
| Synta Pharmaceuticals Corp. | Oral Hsp90 inhibitor therapies for cancer, inflammatory and neurodegenerative diseases. | $ 244,479.24 | |
| T2 Biosystems, Inc | Tacrolimus and Creatinine Project | $ 244,479.25 | |
| T2 Biosystems, Inc | Dx Platform Project | $ 244,479.25 | |
| T2 Biosystems, Inc. | Candida Project | $ 244,479.25 | |
| Taligen Therapeutics, Inc. | TT30 therapeutic recombinant fusion protein to modulate Complement system | $ 244,479.24 | |
| Targeted Cell Therapies, LLC | Development of a Novel Oral Delivery Technology or Large Molecule Therapeutics | $ 73,440.50 | $ 131,500.00 |
| TARIS Biomedical Inc | A novel drug-device combination prod. To improve the treatment of superficial bladder cancer | $ 244,479.25 | |
| Taris Biomedical, Inc | LiRIS: A novel local therapy for the management of discomfort associated with ureteral stent | $ 244,479.25 | |
| TARIS Biomedical, Inc | LiRIS: A novel drug-device combination product for the treatment of Interstitial Cystitis | $ 244,479.25 | |
| Temple Therapeutics, LLC | New Therapies for Cancer using Mesenchymal Stem Cells (MSC's) expressing TRAIL | $ 244,479.25 | |
| Tepha Inc | Hernia Mesh with Therapeutic Coating | $ 244,479.24 | |
| Tetraphase Pharmaceuticals Inc | TP-834:A Promising New Oral Antibiotic for Community Acquired Pneumonia(CABP) | $ 244,479.25 | |
| Tetraphase Pharmaceuticals, Inc. | TP-434: A Potent New Antibiotic To Treat a Broad Range of Multi-Drug Resistant "Superbugs" 834:A Promising New Oral Antibiotic for Community Acquired Pneumonia(CABP) | $ 244,479.25 | |
| Tetraphase Pharmaceuticals, Inc. | TP-2758: A Novel and Exciting Oral Antibiotic for Complicated Urinary Tract Infections (cUTI) | $ 244,479.25 | |
| Theracrine Inc | Monoclonal antibodies targeting cancer-specific osteopontin (vOPN) | $ 244,479.24 | |
| Theracrine, Inc | Dual CXCR/1CXCR2 Inhibitor for the Treatment of Metastatic Cancer | $ 244,479.25 | |
| Theracrine, Inc | Fascin inhibitor for the Treatment of metastatic Cancer | $ 244,479.24 | |
| Tokai Pharmaceuticals, Inc. | TOK-001 | $ 244,479.25 | |
| Tolerx, Inc. | Development of a Targeted Immunotherapeutic for the Treatment of Type 1 Diabetes. | $ 244,479.24 | |
| Tolerx, Inc. | Development of Novel Anti-ILT Immunotherapeutics for the Treatment of Cancer | $ 110,144.11 | $ 134,335.13 |
| Tolerx, Inc. | Development of a Novel Anti-GITR Monoclonal Antibody as an Immunotherapy for Cancer. | $ 244,479.24 | |
| Tomophase Corporation | Optical Coherence Tomographic Imaging System (OCTIS ™ ) | $ 242,476.00 | $ 2,003.24 |
| Translational Therapeutics Inc. | Cancer Therapeutics System | $ 55,532.00 | $ 188,947.25 |
| U.S. Genomics Inc | Highly Multiplexed Infectious Disease Diagnostics Based on Single Molecule DNA Analysis | $ 244,479.25 | |
| VANAS ONCOLOGY, INC | BCP-21, A Novel Anti-Cancer Molecule | $ 136,512.91 | $ 107,966.33 |
| Variation Biotechnologies (US), Inc c/o Variation Biotechnologies Inc | Thermostable Vaccine | $ 244,479.25 | |
| Variation Biotechnologies (US), Inc, c/o Variation Biotechnologies Inc. | Oral Shigella Vaccine | $ 244,479.25 | |
| Variation Biotechnologies (US), Inc. | Variosite Technology | $ 235,077.50 | $ 9,401.75 |
| Variation Biotechnologies (US), Inc. c/o Variation Biotechnologies Inc. | Oral Vaccine | $ 244,479.25 | |
| VasoTech, Inc. | A Novel Drug-Eluting Stent -- Power Stent ® -- for Coronary Arterial Disease Treatment | $ 110,119.50 | $ 134,359.75 |
| Velico Medical, INC | Refrigerated Platelets | $ 7,500.00 | $ 59,733.00 |
| VELICO MEDICAL, INC. | SPRAY DRIED PLASMA | $ 244,479.25 | |
| Verax Biomedical Incorporated | PGD Platelet Test Device | $ 244,479.24 | |
| Veritas Health Solutions LLC | Information Technology Management of Adolescent Depression (iTAD) | $ 53,427.50 | $ 11,455.50 |
| Virdante Pharmaceuticals, Inc | sFc-Recombinant Sialylated Immunoglobulin G (lgG) Fc fragments | $ 244,479.24 | |
| Virdante Pharmaceuticals, Inc | Svig - Siaylated Intravenous Immunoglobulin | $ 244,479.24 | |
| Visterra, Inc (f/k/a Parasol Therapeutics, Inc | PAR401: A Potent, Selective Anti-Influenza Therapeutic and Prophylactic | $ 244,479.24 | |
| ViThera LLC | Development of an engineered bacterial therapy of Inflammatory Bowel Disease | $ 5,739.16 | $ 216,250.00 |
| Vortex Medical Inc | AngioVac | $ 244,479.24 | |
| Wadsworth Medical Technologies, Inc. | Novel Device to Reduce Surgical Site Infection | $ 71,683.00 | $ 172,796.24 |
| X-BODY, Inc | XB-387, a PDGFRB Antibody Therapeutic for Non-Small Cell Lung Cancer | $ 244,479.24 | |
| Xcellerex Inc | XRX-001 Inactivated Yellow Fever Vaccine | $ 244,479.24 | |
| Zafgen Inc | T2D Program | $ 244,479.25 | |
| Zafgen, Inc. | ZGN-440 | $ 244,479.25 | |
| ZIOPHARM Oncology, Inc. | Indibulin | $ 244,479.25 | |
| ZIOPHARM Oncology, Inc. | Palifosfamide | $ 244,479.25 | |
| ZIOPHARM Oncology, Inc. | Darinaparsin | $ 244,479.25 |
References/Related Topics
Page Last Reviewed or Updated: 2012-10-12
